AU2016335767B2 - Methods of treating injuries or conditions related to CNS edema - Google Patents

Methods of treating injuries or conditions related to CNS edema Download PDF

Info

Publication number
AU2016335767B2
AU2016335767B2 AU2016335767A AU2016335767A AU2016335767B2 AU 2016335767 B2 AU2016335767 B2 AU 2016335767B2 AU 2016335767 A AU2016335767 A AU 2016335767A AU 2016335767 A AU2016335767 A AU 2016335767A AU 2016335767 B2 AU2016335767 B2 AU 2016335767B2
Authority
AU
Australia
Prior art keywords
hours
subject
sur1
injury
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016335767A
Other languages
English (en)
Other versions
AU2016335767A8 (en
AU2016335767A1 (en
Inventor
Sven Martin Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remedy Pharmaceuticals Inc
Original Assignee
Remedy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedy Pharmaceuticals Inc filed Critical Remedy Pharmaceuticals Inc
Publication of AU2016335767A1 publication Critical patent/AU2016335767A1/en
Publication of AU2016335767A8 publication Critical patent/AU2016335767A8/en
Application granted granted Critical
Publication of AU2016335767B2 publication Critical patent/AU2016335767B2/en
Priority to AU2022279369A priority Critical patent/AU2022279369B2/en
Assigned to REMEDY PHARMACEUTICALS, INC. reassignment REMEDY PHARMACEUTICALS, INC. Request for Assignment Assignors: BIOGEN CHESAPEAKE LLC
Priority to AU2025202620A priority patent/AU2025202620A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016335767A 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to CNS edema Active AU2016335767B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022279369A AU2022279369B2 (en) 2015-10-07 2022-11-28 Methods of treating injuries or conditions related to CNS edema
AU2025202620A AU2025202620A1 (en) 2015-10-07 2025-04-14 Methods of treating injuries or conditions related to CNS edema

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562238461P 2015-10-07 2015-10-07
US62/238,461 2015-10-07
PCT/US2016/055988 WO2017062765A1 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to cns edema

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022279369A Division AU2022279369B2 (en) 2015-10-07 2022-11-28 Methods of treating injuries or conditions related to CNS edema

Publications (3)

Publication Number Publication Date
AU2016335767A1 AU2016335767A1 (en) 2018-05-24
AU2016335767A8 AU2016335767A8 (en) 2018-06-28
AU2016335767B2 true AU2016335767B2 (en) 2022-10-06

Family

ID=58488580

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016335767A Active AU2016335767B2 (en) 2015-10-07 2016-10-07 Methods of treating injuries or conditions related to CNS edema
AU2022279369A Active AU2022279369B2 (en) 2015-10-07 2022-11-28 Methods of treating injuries or conditions related to CNS edema
AU2025202620A Pending AU2025202620A1 (en) 2015-10-07 2025-04-14 Methods of treating injuries or conditions related to CNS edema

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022279369A Active AU2022279369B2 (en) 2015-10-07 2022-11-28 Methods of treating injuries or conditions related to CNS edema
AU2025202620A Pending AU2025202620A1 (en) 2015-10-07 2025-04-14 Methods of treating injuries or conditions related to CNS edema

Country Status (15)

Country Link
US (4) US20180280325A1 (enExample)
EP (1) EP3359162B1 (enExample)
JP (4) JP7349786B2 (enExample)
KR (2) KR20240105519A (enExample)
CN (2) CN108348534A (enExample)
AU (3) AU2016335767B2 (enExample)
BR (1) BR112018006925A2 (enExample)
CA (1) CA3001321A1 (enExample)
EA (1) EA201890893A1 (enExample)
ES (1) ES2940669T3 (enExample)
HK (1) HK1257542A1 (enExample)
IL (1) IL258509B2 (enExample)
MA (1) MA45574A (enExample)
MX (1) MX392466B (enExample)
WO (1) WO2017062765A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014027983B1 (pt) 2012-05-08 2022-05-24 Aeromics, Inc Uso de inibidores de aquaporina seletivos
WO2015069961A1 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel prodrug salts
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법
WO2020041905A1 (en) * 2018-08-31 2020-03-05 The University Of British Columbia Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds
CN113874002A (zh) * 2019-05-02 2021-12-31 生物切萨皮克有限责任公司 治疗患有中枢神经系统挫伤的受试者的方法
TW202214561A (zh) * 2020-07-17 2022-04-16 大陸商上海森輝醫藥有限公司 磺醯脲類衍生物及其醫藥用途
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212189A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema using a sur1-trpm4 channel inhibitor
WO2025212155A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212154A1 (en) * 2024-04-05 2025-10-09 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276411A1 (en) * 2002-03-20 2006-12-07 University Of Maryland, Baltimore Novel non-selective cation channel in neuronal cells and methods for treating brain swelling
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
DK2438913T3 (da) * 2002-03-20 2020-06-22 Univ Maryland Ikke-selektiv kationkanal i neurale celler og forbindelser, der blokerer kanalen, til anvendelse i behandling af opsvulmning af hjernen
US20050246000A1 (en) * 2004-05-03 2005-11-03 Seacoast Technologies, Inc. Cooled craniectomy
EP2167107B1 (en) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
KR20240105519A (ko) * 2015-10-07 2024-07-05 레메디 파마슈티칼즈, 인크. Cns 부종과 관련한 손상 또는 병태의 치료 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276411A1 (en) * 2002-03-20 2006-12-07 University Of Maryland, Baltimore Novel non-selective cation channel in neuronal cells and methods for treating brain swelling
US8277845B2 (en) * 2007-12-04 2012-10-02 Remedy Pharmaceuticals, Inc. Formulations and methods for lyophilization and lyophilates provided thereby
US20130203853A1 (en) * 2010-07-19 2013-08-08 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KURLAND et al.: "Glibenclamide for the treatment of acute CNS injury.", PHARMACEUTICALS, 2013, vol. 6, pages 1287 - 1303 *
SHETH et al.: "Exploratory analysis of glyburide as a novel therapy for preventing brain swelling.", NEUROCRITICAL CARE, 2015 May, vol. 21, no. 1, pages 43 - 51 *

Also Published As

Publication number Publication date
AU2016335767A8 (en) 2018-06-28
IL258509B (en) 2022-12-01
IL258509B2 (en) 2023-04-01
JP2023053274A (ja) 2023-04-12
KR20180063296A (ko) 2018-06-11
JP2021073317A (ja) 2021-05-13
WO2017062765A1 (en) 2017-04-13
BR112018006925A2 (pt) 2018-10-16
US20250017880A1 (en) 2025-01-16
CA3001321A1 (en) 2017-04-13
EP3359162A1 (en) 2018-08-15
MX392466B (es) 2025-03-24
EP3359162A4 (en) 2019-08-28
IL258509A (en) 2018-05-31
JP2024164167A (ja) 2024-11-26
US20240216309A1 (en) 2024-07-04
CN108348534A (zh) 2018-07-31
US11951085B2 (en) 2024-04-09
JP7349786B2 (ja) 2023-09-25
EP3359162B1 (en) 2022-12-21
AU2022279369B2 (en) 2025-02-13
AU2022279369A1 (en) 2023-01-19
JP7592768B2 (ja) 2024-12-02
KR102681027B1 (ko) 2024-07-02
ES2940669T3 (es) 2023-05-10
KR20240105519A (ko) 2024-07-05
HK1257542A1 (zh) 2019-10-25
JP2018530564A (ja) 2018-10-18
US20180280325A1 (en) 2018-10-04
AU2025202620A1 (en) 2025-05-01
AU2016335767A1 (en) 2018-05-24
MX2018004286A (es) 2018-08-09
US20220125750A1 (en) 2022-04-28
EA201890893A1 (ru) 2018-09-28
CN115737816A (zh) 2023-03-07
MA45574A (fr) 2019-05-15

Similar Documents

Publication Publication Date Title
AU2022279369B2 (en) Methods of treating injuries or conditions related to CNS edema
US12251389B1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
BR112021002945A2 (pt) dosagem noturna crônica de lasmiditan para prevenção de enxaqueca
US20250345346A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Fogarty-Mack et al. Superselective intraarterial papaverine administration: effect on regional cerebral blood flow in patients with arteriovenous malformations
Bubalo et al. Randomized open-label trial of dolasetron for the control of nausea and vomiting associated with high-dose chemotherapy with hematopoietic stem cell transplantation
JP2022546042A (ja) 小児対象のｃｌｎ２疾患を治療するための方法
US20220226353A1 (en) Method for treating subjects suffering from central nervous system contusions
Khijmatgar et al. Observational studies on the efficacy of carbamazepine and ascorbyl palmitate in managing trigeminal neuralgia
US20250325564A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
Baig et al. NFB-06. TREATMENT CHALLENGES IN PEDIATRIC GLIOBLASTOMA MULTIFORME WITH CONCURRENT SOMATIC AND GERMLINE NF1 MUTATIONS WITH GERMLINE MISMATCH REPAIR MUTATIONS: TWO UNIQUE CASES
Yılmaz et al. The Association Between Joint Laxity and Post-Dural Puncture Headache
WO2025193971A1 (en) Methods of treating and reducing the likelihood of developing epilepsy
WO2025212154A1 (en) Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
WO2025212155A1 (en) Methods of treating ischemic stroke with large vessel occlusion using a sur1-trpm4 channel inhibitor
Hasanein et al. Extending labor epidural analgesia using lidocaine plus either dexmedetomidine or epinephrine for emergency cesarean section
JP2011500617A (ja) 血栓溶解についての新規な患者亜群

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 32 , NO 19 , PAGE(S) 2821 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME REMEDY PHARMACEUTICALS, INC., APPLICATION NO.2016335767, UNDER INID (71) CORRECT THE APPLICANT NAME TO BIOGEN CHESAPEAKE LLC

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: REMEDY PHARMACEUTICALS, INC.

Free format text: FORMER OWNER(S): BIOGEN CHESAPEAKE LLC